Skip Content
You are currently on the new version of our website. Access the old version .

Antibodies, Volume 13, Issue 4

2024 December - 27 articles

Cover Story: Background/Objectives: Mucin-1 (MUC1) is a transmembrane glycoprotein that is overexpressed and hypoglycosylated in premalignant and malignant epithelial cells compared to normal cells, creating a target antigen for humoral and cellular immunity. Healthy individuals with a history of advanced colonic adenomas and at high risk for colon cancer were enrolled in a clinical trial to evaluate the feasibility of using a MUC1 peptide vaccine to prevent colon cancer. Anti-MUC1 antibodies elicited by this vaccine were cloned using peripheral blood B cells and sera collected two weeks after a one-year booster. Twelve of these fully human monoclonal antibodies (mAb) were tested for binding to MUC1+ target cells, and three with the highest binding were further evaluated for various effector functions important for tumor rejection. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (27)

  • Article
  • Open Access
3,123 Views
16 Pages

Some Human Anti-Glycan Antibodies Lack the Ability to Activate the Complement System

  • Nadezhda Shilova,
  • Alexey Nokel,
  • Alexander Lipatnikov,
  • Nailya Khasbiullina,
  • Yuri Knirel,
  • Ludmila Baidakova,
  • Alexander Tuzikov,
  • Sergei Khaidukov,
  • Polina Obukhova and
  • Nicolai Bovin
  • + 4 authors

23 December 2024

Background. Naturally occurring human antibodies against glycans recognize and quickly eliminate infectious bacteria, viruses and aberrantly glycosylated neoplastic malignant cells, and they often initiate processes that involve the complement system...

  • Article
  • Open Access
2,770 Views
21 Pages

Integrating In Silico and In Vitro Tools for Optimized Antibody Development—Design of Therapeutic Anti-oxMIF Antibodies

  • Gregor Rossmueller,
  • Irina Mirkina,
  • Michael Thiele,
  • Alejandro Puchol Tarazona,
  • Florian Rueker,
  • Randolf J. Kerschbaumer and
  • Alexander Schinagl

20 December 2024

Background: Rigorous assessment of antibody developability is crucial for optimizing lead candidates before progressing to clinical studies. Recent advances in predictive tools for protein structures, surface properties, stability, and immunogenicity...

  • Article
  • Open Access
2 Citations
2,781 Views
13 Pages

Clinical Characteristics, Comorbidities, and Treatment in Patients with Pemphigus—A Single-Center Retrospective Study

  • Natalia Welc,
  • Sandra Ważniewicz,
  • Paweł Głuszak,
  • Maciej Spałek,
  • Agnieszka Seraszek-Jaros,
  • Magdalena Jałowska and
  • Marian Dmochowski

13 December 2024

Background/Objectives: Pemphigus comprises a diverse group of disorders within the autoimmune bullous dermatoses (AIBDs) spectrum. Among these, pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the most commonly encountered variants. Despite i...

  • Article
  • Open Access
1 Citations
2,726 Views
13 Pages

Intensity of Intrathecal Total IgG Synthesis in Multiple Sclerosis Correlates with the Degree of Pleocytosis, Diversity of Intrathecal Antiviral Antibody Specificities, and Female Sex

  • Benjamin Vlad,
  • Marc Hilty,
  • Stephan Neidhart,
  • Klara Asplund Högelin,
  • Mario Ziegler,
  • Mohsen Khademi,
  • Andreas Lutterotti,
  • Axel Regeniter,
  • Roland Martin and
  • Ilijas Jelcic
  • + 1 author

12 December 2024

Background: The presence of intrathecal total IgG production is a hallmark of cerebrospinal fluid (CSF) characteristics in multiple sclerosis (MS). Herein, we systematically analyze how the intensity (instead of mere presence) of intrathecal total Ig...

  • Article
  • Open Access
3,201 Views
22 Pages

A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)

  • Reeder M. Robinson,
  • Leticia Reyes,
  • Benjamin N. Christopher,
  • Ravyn M. Duncan,
  • Rachel A. Burge,
  • Julie Siegel,
  • Patrick Nasarre,
  • Pingping Wang,
  • John P. O’Bryan and
  • Nathan G. Dolloff
  • + 2 authors

5 December 2024

Background/Objectives: Anterior Gradient-2 (AGR2/PDIA17) is a member of the protein disulfide isomerase (PDI) family of oxidoreductases. AGR2 is up-regulated in several solid tumors, including pancreatic ductal adenocarcinoma (PDAC). Given the dire n...

  • Brief Report
  • Open Access
2 Citations
2,318 Views
10 Pages

An Improved Theileria parva Sporozoite Seroneutralization Assay for the Identification of East Coast Fever Immune Correlates

  • Hannah Chege,
  • Samuel Githigia,
  • James Gathumbi,
  • Naomi Chege,
  • Rose Ojuok,
  • Josiah Odaba,
  • Stephen Mwalimu,
  • Harriet Oboge,
  • Lucilla Steinaa and
  • Anna Lacasta
  • + 1 author

5 December 2024

Background: Immune correlates of protection are ideal tools to predict treatment or vaccine efficacy. However, the accuracy of the immune correlate and the capability to robustly predict the outcome of a vaccine candidate are determined by the perfor...

  • Article
  • Open Access
3 Citations
6,642 Views
23 Pages

4 December 2024

Background: The complementarity-determining region (CDR) of antibodies represents the most diverse region both in terms of sequence and structural characteristics, playing the most critical role in antibody recognition and binding for immune response...

  • Article
  • Open Access
5 Citations
5,625 Views
20 Pages

29 November 2024

Background/Objectives: Salivary immunoglobulin A (IgA) is a mediator of local immunity and host defence. Altered IgA levels may predispose to bacterial invasion of the mucosa in the gastrointestinal tract, including the oral cavity. Our study aimed t...

  • Article
  • Open Access
1 Citations
3,147 Views
17 Pages

Development of BCMA-Targeted Bispecific Natural Killer Cell Engagers for Multiple Myeloma Treatment

  • Minchuan Zhang,
  • Han Ping Loh,
  • Shiyi Goh Fang,
  • Yuansheng Yang,
  • Kong-Peng Lam and
  • Shengli Xu

29 November 2024

Background: B-cell maturation antigen (BCMA)-targeted T cell-redirecting immunotherapies, including Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell engagers have demonstrated remarkable success in treating relapsed/refractory (RR) multiple...

  • Article
  • Open Access
1,504 Views
13 Pages

Increased Levels of Anti-Anisakis Antibodies During Hospital Admission in Septic Patients

  • Juan Carlos Andreu-Ballester,
  • Amparo Navarro,
  • Miguel Angel Arribas,
  • Moises Rico,
  • Laura Albert,
  • Carlos García-Ballesteros,
  • Lorena Galindo-Regal,
  • Rosa Sorando-Serra,
  • Francisca López-Chuliá and
  • Carmen Cuéllar
  • + 3 authors

27 November 2024

Background/Objectives: In a previous study, we described elevated anti-Anisakis IgG levels in septic patients in relation to disease severity. In this study, our objective was to analyze the evolution of anti-Anisakis immunoglobulins in septic patien...

  • Review
  • Open Access
6 Citations
2,703 Views
8 Pages

22 November 2024

Paraneoplastic pemphigus (PNP) is a rare autoimmune disorder associated with underlying neoplasms, predominantly Non-Hodgkin Lymphomas, affecting adults aged 45 to 70. This review analyzed 87 articles from MEDLINE/PubMed, Ovid and Scopus focusing on...

  • Article
  • Open Access
3 Citations
3,044 Views
12 Pages

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model

  • Fentian Chen,
  • Kexin Wu,
  • Shiqi Lin,
  • Jinlong Cui,
  • Xiaoqing Chen,
  • Zhiren Zeng,
  • Na Yuan,
  • Mujin Fang,
  • Xue Liu and
  • Wenxin Luo
  • + 1 author

20 November 2024

Background: Although immune checkpoint inhibitors (ICIs) have demonstrated efficacy in treating advanced cancers, their therapeutic success remains limited for many patients, with initial responders often experiencing resistance and relapse. Interleu...

  • Article
  • Open Access
2 Citations
3,443 Views
14 Pages

Generation, Characterization, and Preclinical Studies of a Novel NKG2A-Targeted Antibody BRY805 for Cancer Immunotherapy

  • Yaqiong Zhou,
  • Yiru Wang,
  • Jinfeng Liang,
  • Jing Qian,
  • Zhenhua Wu,
  • Zhangzhao Gao,
  • Jian Qi,
  • Shanshan Zhu,
  • Na Li and
  • Haibin Wang
  • + 4 authors

20 November 2024

Immuno-oncology has revolutionized cancer treatment, with NKG2A emerging as a novel target for immunotherapy. The blockade of NKG2A using the immune checkpoint inhibitor (ICI) monalizumab has been shown to enhance the responses of both NK cells and C...

  • Communication
  • Open Access
1,685 Views
10 Pages

High Prevalence of aCL-IgA and aβ2GPI-IgA in Drug-Free Schizophrenia Patients: Evidence of a Potential Autoimmune Link

  • Samar Samoud,
  • Imen Zamali,
  • Fatma Korbi,
  • Ahlem Mtiraoui,
  • Ahlem Ben Hmid,
  • Neila Hannachi,
  • Yousr Galai,
  • Hechmi Louzir and
  • Yousri El Kissi

15 November 2024

Background/Objectives: Schizophrenia (SZ) is a complex psychiatric disorder with increasing evidence pointing to an autoimmune component, including the presence of antiphospholipid antibodies (aPLs). This study aims to assess the prevalence of antica...

  • Article
  • Open Access
3,191 Views
13 Pages

Ocular Mucous Membrane Pemphigoid Demonstrates a Distinct Autoantibody Profile from Those of Other Autoimmune Blistering Diseases: A Preliminary Study

  • Yingzi Liu,
  • Lei Bao,
  • Dharm Sodha,
  • Jing Li,
  • Adrian Mansini,
  • Ali R. Djalilian,
  • Xiaoguang Li,
  • Hua Qian,
  • Norito Ishii and
  • Kyle T. Amber
  • + 1 author

14 November 2024

Background: Ocular predominant mucous membrane pemphigoid (oMMP) is a severe subtype of autoimmune blistering disease (AIBD), which can result in scarring and vision loss. The diagnosis of oMMP is challenging as patients often have undetectable level...

  • Review
  • Open Access
2 Citations
8,463 Views
25 Pages

11 November 2024

This review briefly traces the historical development of antibody research and related technologies. The path from early perceptions of immunity to the emergence of modern immunotherapy has been marked by pivotal discoveries and technological advance...

  • Article
  • Open Access
6 Citations
3,491 Views
18 Pages

29 October 2024

When developing immunochemical test systems, it is necessary to obtain specific antibodies. Their quality depends, among other things, on the immunogen used. When preparing hapten–protein conjugates to obtain antibodies for low-molecular-weight...

  • Review
  • Open Access
7 Citations
4,360 Views
14 Pages

18 October 2024

Background/Objectives: Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, though advances in targeted therapies have improved treatment outcomes. The mesenchymal–epithelial transition (MET) gene plays a sig...

  • Article
  • Open Access
1 Citations
2,545 Views
11 Pages

Limited Biomarker Potential for IgG Autoantibodies Reactive to Linear Epitopes in Systemic Lupus Erythematosus or Spondyloarthropathy

  • S. Janna Bashar,
  • Zihao Zheng,
  • Aisha M. Mergaert,
  • Ryan R. Adyniec,
  • Srishti Gupta,
  • Maya F. Amjadi,
  • Sara S. McCoy,
  • Michael A. Newton and
  • Miriam A. Shelef

12 October 2024

Background: Autoantibodies are commonly used as biomarkers in autoimmune diseases, but there are limitations. For example, autoantibody biomarkers have poor sensitivity or specificity in systemic lupus erythematosus and do not exist in the spondyloar...

  • Review
  • Open Access
9 Citations
5,440 Views
26 Pages

Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies

  • Yuan Zong,
  • Miki Miyagaki,
  • Mingming Yang,
  • Jing Zhang,
  • Yaru Zou,
  • Kyoko Ohno-Matsui and
  • Koju Kamoi

11 October 2024

Background: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular c...

  • Article
  • Open Access
2 Citations
5,058 Views
20 Pages

Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions

  • Michelle L. McKeague,
  • Jason Lohmueller,
  • Matthew T. Dracz,
  • Najla Saadallah,
  • Eric D. Ricci,
  • Donella M. Beckwith,
  • Ramya Ayyalasomayajula,
  • Maré Cudic and
  • Olivera J. Finn

10 October 2024

Background/Objectives: Mucin-1 (MUC1) is a transmembrane glycoprotein that is overexpressed and hypoglycosylated in premalignant and malignant epithelial cells compared to normal cells, creating a target antigen for humoral and cellular immunity. Hea...

  • Review
  • Open Access
6 Citations
4,817 Views
23 Pages

B Cell and Antibody Responses in Bovine Tuberculosis

  • Laura Inés Klepp,
  • Federico Carlos Blanco,
  • María Mercedes Bigi,
  • Cristina Lourdes Vázquez,
  • Elizabeth Andrea García,
  • Julia Sabio y García and
  • Fabiana Bigi

9 October 2024

The development of vaccines and effective diagnostic methods for bovine tuberculosis requires an understanding of the immune response against its causative agent, Mycobacterium bovis. Although this disease is primarily investigated and diagnosed thro...

  • Article
  • Open Access
1 Citations
2,908 Views
15 Pages

Metabolic Engineering of Glycofusion Bispecific Antibodies for α-Dystroglycanopathies

  • Xiaotian Zhong,
  • Guoying Grace Yan,
  • Apurva Chaturvedi,
  • Xiuling Li,
  • Yijie Gao,
  • Mahasweta Girgenrath,
  • Chris J. Corcoran,
  • Liz Diblasio-Smith,
  • Edward R. LaVallie and
  • Aaron M. D’Antona
  • + 7 authors

7 October 2024

Background: α-dystroglycanopathies are congenital muscular dystrophies in which genetic mutations cause the decrease or absence of a unique and complex O-linked glycan called matriglycan. This hypoglycosylation of O-linked matriglycan on the &a...

  • Article
  • Open Access
3 Citations
5,149 Views
12 Pages

Development of a Mammalian Cell Line for Stable Production of Anti-PD-1

  • Erika Csató-Kovács,
  • Pál Salamon,
  • Szilvia Fikó-Lászlo,
  • Krisztina Kovács,
  • Alice Koka,
  • Mónika András-Korodi,
  • Emőke Antal,
  • Emília Brumă,
  • Brigitta Tőrsők and
  • Beáta Albert
  • + 5 authors

3 October 2024

Background/Objectives: Immune checkpoint blockade, particularly targeting the programmed cell death 1 (PD-1) receptor, is a promising strategy in cancer immunotherapy. The interaction between PD-1 and its ligands, PD-L1 and PD-L2, is crucial in immun...

  • Article
  • Open Access
3 Citations
3,377 Views
8 Pages

Measurement of the Memory B Cell Response via Antibodies from Activated Cells

  • Caroline Rockstroh,
  • Katja Hintz,
  • Judith Kannenberg and
  • Christian Jassoy

3 October 2024

Background/Objectives: The body’s immune response to infections and vaccination leads to the formation of memory B cells (MBCs), which protect against future infections. MBCs circulate in the blood, and the strength of the MBC response is measured wi...

  • Systematic Review
  • Open Access
3 Citations
4,015 Views
19 Pages

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma

  • Olga Lytvynova,
  • Jenna Jwayyed,
  • Daniel Pastel,
  • Rohan Prasad,
  • Jack Khouri,
  • Louis Williams,
  • Sandra Mazzoni,
  • Shahzad Raza and
  • Faiz Anwer

29 September 2024

Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patie...

  • Review
  • Open Access
12 Citations
9,969 Views
15 Pages

Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature

  • Panagiotis Gklinos,
  • Fotios Athanasopoulos,
  • Vagia Giatrakou,
  • Nikolaos-Achilleas Arkoudis,
  • Dorothea Pournara,
  • Eirini Giagkou,
  • Argyro Tountopoulou,
  • Sofia Vassilopoulou and
  • Dimos-Dimitrios Mitsikostas

25 September 2024

Background: Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy, which was first identified in 2016, is an immune-mediated inflammatory disorder of the nervous system characterized by antibodies targeting GFAP. The exact pathogenic mecha...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Antibodies - ISSN 2073-4468